Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences
Rhea-AI Summary
Pacira BioSciences (Nasdaq:PCRX) will join analyst-led fireside chats at three major healthcare conferences in May and June 2026: RBC Capital Markets, Jefferies, and Goldman Sachs. Live audio webcasts and two-week replays will be available on the company’s investor website under the Events section.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – PCRX
On the day this news was published, PCRX gained 0.88%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PCRX showed a modest 0.44% gain while key peers were mixed: AMPH down 4.94%, HROW down 14.29%, COLL down 0.17%, and DVAX up 0.06%. Momentum scans only flagged EVO down 11.33%, suggesting today’s move was stock-specific rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 08 | Inducement grants | Neutral | -2.1% | Equity awards granted to new employees under inducement plan. |
| May 05 | Shareholder letter | Neutral | -4.4% | Company mailed communication directly to stockholders ahead of meeting. |
| Apr 30 | Q1 2026 earnings | Positive | -4.1% | Revenue growth, guidance reiteration, buybacks and pipeline progress reported. |
| Apr 28 | Proxy materials | Positive | -1.1% | Definitive proxy filing highlighting strategy, stock performance and repurchases. |
| Apr 27 | Real-world EXPAREL data | Positive | +4.2% | Study showed lower opioid use and medical costs with EXPAREL in hip surgery. |
Recent months show several negative price reactions to generally constructive announcements, including earnings and shareholder communications, while positive clinical data drew the strongest upside response.
Over the last few weeks, Pacira has reported Q1 2026 results with $177.4M revenue and reiterated 2026 guidance, filed definitive proxy materials emphasizing its 5x30 strategy and share repurchases above $200M, and issued real‑world EXPAREL data showing lower opioid use and costs, which saw a 4.24% gain. Routine corporate items like inducement grants and shareholder letters often coincided with modest share pressure. Today’s conference-participation news fits the pattern of non-fundamental updates.
Market Pulse Summary
This announcement outlines Pacira’s participation in three upcoming healthcare conferences, providing additional venues for management to communicate strategy and portfolio progress. In recent months, the company has reported Q1 2026 results, reiterated guidance, highlighted EXPAREL real‑world data, and engaged shareholders via proxy materials and letters. Investors may watch for any new clinical, commercial, or governance commentary emerging from these fireside chats that could supplement the largely informational nature of this release.
AI-generated analysis. Not financial advice.
BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in analyst-led fireside chats at the following three healthcare conferences:
- 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20th at 8:30AM ET.
- 2026 Jefferies Global Healthcare Conference on Wednesday, June 3rd at 9:55AM ET.
- Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Monday, June 8th at 1:20PM ET.
Live audio of the events can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.
Company Contact: Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 Christian.pedetti@pacira.com